Cited by 1Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Corrigendum: The Research Progress of Direct KRAS G12C Mutation Inhibitors

Open access
Yang, Ai, Li, Min, Fang, Mingzhi·2022·Pathology and Oncology Research

Abstract

In the original article, there was some mistakes in the legend for all of the figure as published. I didn't annotate the source of the pictures cited in the article. The correct legend appears below. I apologize for this error and state that authorization has been obtained from the author of each picture, and this does not change the scientific conclusions of the article in any way. The original article has been updated. Figures, tables, and images will be published under a Creative Commons CC-BY licence and permission must be obtained for use of copyrighted material from other sources (including republished/adapted/modified/partial figures and images from the internet). It is the responsibility of the authors to acquire the licenses, to follow any citation instructions requested by third-party rights holders, and cover any supplementary charges.

Integrity signals

Registry

Crossref · 10.3389/pore.2021.1610250

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [14]Huili L Fei J Jiwei R Tao L Yadong C. Research Advances on KRAS and Its Inhibitors. Acta Pharmaceutica Sinica (2020) 44(1): 43– 55.
  2. [20]Xin L Yijun W and Pingyu L. Recent Advancement In Targeting The KRASG12C Mutant For Cancer Therapy. Acta Pharmaceutica Sinica (2021) 56(2): 374– 82.

Cited by

Sorted by citations

Authors
Yang, A., Li, M., & Fang, M.
Affiliations
Nanjing University of Chinese Medicine (CN)
Corresponding author
Li, Min
ORCID
Li, Min
Venue
Pathology and Oncology Research
Published
2022-02-24
Volume
27
Pages
1610250-1610250
ISSN
  • 1219-4956 (ISSN-L)
  • 1532-2807
OpenAlex
W4213456482
Cited by
1
References
4
Citations by year
2023: 1
Type
journal article
Language
en
Open access
Locations
  • Pathology & Oncology Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
KRAS G12C mutation, KRAS inhibitors, figure legend correction, image licensing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review